 |
|
Diabetes Mellitus—A Call for Papers
Catherine D. DeAngelis, MD, MPH;
David S. Cooper, MD;
Phil B. Fontanarosa, MD, MBA
JAMA. 2008;300(4):441.
For the second time this decade, JAMA will publish a theme issue devoted to the topic of diabetes mellitus. While some progress has been made in understanding and managing diabetes since the May 15, 2002, theme issue,1 the epidemic continues, as does JAMA's strong interest in this problem.
In 2000 the worldwide prevalence of diabetes was estimated to be 2.8% and is projected to reach 4.4% by 2030.2 In 2005, the total prevalence of diabetes among all ages for those born in the United States was 20.8 million individuals (7% of the population), and an estimated 30% of the cases were undiagnosed.3 The estimated lifetime risk of developing diabetes for individuals in the United States is 32.8% for men and 38.5% for women.4
By virtue of the disease process and its associated complications, individuals with diabetes have substantial reductions in life expectancy and quality of life. Research to help counteract these outcomes in patients with diabetes has resulted in a number of new and advanced therapies, including novel antidiabetes medications,5-7 surgical interventions,8-9 islet cell transplantation,10 hematopoietic stem cell transplantation,11 and gene therapy.12
Because of the continued challenges of diabetes and its associated comorbidities, JAMA will devote an entire issue to this topic in April 2009. This theme issue will be in conjunction with all 9 of our Archives family of specialty journals, which also will devote some or all of their April issues to this topic. We invite authors to submit manuscripts reporting original research (original contributions, preliminary reports, and research letters), systematic reviews, special communications, and commentaries on any topic related to diabetes and its comorbidities. We also welcome articles addressing the economic implications, policy aspects, and ethical considerations relative to diabetes.
Special consideration will be given to randomized trials of new therapies and to research reports addressing the management of diabetes, including glycemic monitoring and new technologies for diabetes care; genetic aspects and prevention; islet cell/pancreatic transplantation and related effects of diabetes on cardiovascular and oncologic disorders.
Manuscripts received by November 1, 2008, will have the best chance of consideration for publication in the diabetes theme issue of JAMA. High-quality articles also may be published in other issues of JAMA or if not suitable for JAMA, may be referred (with the authors' permission) for consideration for publication in one of our Archives specialty journals.
Please consult the instructions for authors for preparing and submitting manuscripts.13 We look forward to receiving your manuscripts for our theme issue devoted to this increasingly important global health problem.
AUTHOR INFORMATION
Financial Disclosures: None reported.
Editorials represent the opinions of the authors and JAMA and not those of the American Medical Association.
Author Affiliations: Dr DeAngelis (cathy.deangelis{at}jama-archives.org) is Editor in Chief, Dr Cooper is Contributing Editor, and Dr Fontanarosa is Executive Deputy Editor, JAMA. Dr Cooper is also with the Division of Endocrinology, Johns Hopkins University School of Medicine.
REFERENCES
|
1. Cooper DS, ed, DeAngelis CD, ed. Diabetes. JAMA. 2002;287(19, theme issue):2461-2994.
FREE FULL TEXT
2. Wild S, Roglic G, Green A; et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
FREE FULL TEXT
3. CDC National Diabetes Fact Sheet, US 2005. http://www.diabetes.org/uedocuments/NationalDiabetesFactSheetRev.pdf. Accessed June 27, 2008.4. Narayan KM, Boyle JP, Thompson TT; et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884-1890.
FREE FULL TEXT
5. Nathan DM. Finding new treatments for diabetes: how many, how fast and how good? N Engl J Med. 2007;356(5):437-440.
FREE FULL TEXT
6. Kuehn BM. New diabetes drugs target gut hormones. JAMA. 2006;296(4):380-381.
FREE FULL TEXT
7. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
FREE FULL TEXT
8. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005;293(12):1501-1508.
FREE FULL TEXT
9. Dixon JB, O'Brien PE, Playfair J; et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316-323.
FREE FULL TEXT
10. Soria B, Skoudy A, Martin F. From stem cells to beta cells: new strategies in cell therapy of diabetes mellitus. Diabetologia. 2001;44(4):407-415.
FULL TEXT
|
ISI
| PUBMED
11. Voltarelli JC, Couri CE, Stracieri AB; et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. JAMA. 2007;297(14):1568-1576.
FREE FULL TEXT
12. Zhang YC, Pileggi A, Agarwal A; et al. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes. 2003;52(3):708-716.
FREE FULL TEXT
13. JAMA instructions for authors. JAMA. 2008;300(1):108-118. http://jama.ama-assn.org/misc/ifora.dtl. Accessed June 26, 2008.
|
